Survival Outcomes and Prognostic Factors of Primary Salivary Gland Malignancy: A 24‐Year Retrospective Cohort Study
ANZ Journal of Surgery · 2026
DOI: 10.1111/ans.70891 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift ANZ Journal of Surgery, 2026. Verfasst von Jacinta Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Carcinoma, Mucoepidermoid. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
Salivary gland malignancy (SGM) is a rare and heterogeneous head and neck neoplasm. Curative treatment often mandates upfront surgery. Patients with high‐risk features receive adjuvant radiotherapy. This study aims to investigate the clinicopathological characteristics, survival outcomes and prognostic factors for primary SGM in an Australian population.
Methods
A retrospective cohort study of adult patients with primary SGM diagnosed between January 2001 and December 2024 at our institution was conducted. Clinicopathological and treatment characteristics were collected. Overall survival (OS), recurrence‐free survival (RFS) and disease‐free survival (DFS) were calculated. Log‐rank univariate analysis and multivariate Cox regression analysis were conducted to determine prognostic factors for OS and DFS.
Results
A total of 149 patients were included. The median follow‐up time was 59 months (IQR 22.75–96 months). Patients were mostly male (57.7%) with a median age of 59 years (IQR 48–71 years). Tumours were most commonly located in the parotid gland (81.2%). The most common histological subtype was mucoepidermoid carcinoma (26.2%). The 5‐ and 10‐year OS, RFS and DFS were 81.9% and 77.9%, 78.5% and 71.8% and 84.6% and 82.6%, respectively. Independent prognostic factors for OS were ECOG 2/3 (HR 19.059, 95% CI [3.061–118.664]), T3/4 (HR 6.925 [2.871–16.703]) and intermediate/high grade (HR 3.310 [1.122–9.761]). Independent prognostic factors for DFS were ECOG 2/3 (HR 64.267 [7.758–532.400]), T3/4 (HR 8.085 [3.008–21.729]) and intermediate/high grade (HR 8.065 [1.774–36.660]).
Conclusions
Survival outcomes for primary SGM significantly differ between subtypes. Independent prognostic factors for OS and DFS are ECOG 2/3, T3/4 and intermediate/high grade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, Head and Neck Surgery, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
- Department of Radiation Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
- Northern Sydney Local Health District Executive, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
ORCID-Profile: Jacinta Lin, Leba M Sarkis, Andrew Wignall, Thomas Eade, Sarah Bergamin, Dasantha Jayamanne, Anna Lawless, Venkatesha Venkatesha, David Veivers
Zitieren
APA
Lin, J., Pang, L., Sarkis, L. M., Wignall, A., Eade, T., Bergamin, S., Jayamanne, D., Lawless, A., Venkatesha, V., & Veivers, D. (2026). Survival Outcomes and Prognostic Factors of Primary Salivary Gland Malignancy: A 24‐Year Retrospective Cohort Study. ANZ Journal of Surgery. https://doi.org/10.1111/ans.70891
Vancouver
Lin J, Pang L, Sarkis LM, Wignall A, Eade T, Bergamin S, et al. Survival Outcomes and Prognostic Factors of Primary Salivary Gland Malignancy: A 24‐Year Retrospective Cohort Study. ANZ Journal of Surgery. 2026. doi:10.1111/ans.70891
BibTeX
@article{Lin2026,
author = {Lin, Jacinta and Pang, Leo and Sarkis, Leba M and Wignall, Andrew and Eade, Thomas and Bergamin, Sarah and Jayamanne, Dasantha and Lawless, Anna and Venkatesha, Venkatesha and Veivers, David},
title = {Survival Outcomes and Prognostic Factors of Primary Salivary Gland Malignancy: A 24‐Year Retrospective Cohort Study},
journal = {ANZ Journal of Surgery},
year = {2026},
doi = {10.1111/ans.70891}
}
EUVIMED